Why Analyst Says Rare Disease-Focused Inozyme Pharma Stock 'Could Be Worth A Look'
Stifel Maintains Inozyme Pharma(INZY.US) With Buy Rating, Maintains Target Price $16
Stifel analyst Dae Gon Ha maintains $Inozyme Pharma(INZY.US)$ with a buy rating, and maintains the target price at $16.According to TipRanks data, the analyst has a success rate of 46.0% and a total
This AutoNation Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Inozyme Pharma Initiated at Buy by Stifel
Stifel Initiates Inozyme Pharma(INZY.US) With Buy Rating, Announces Target Price $16
Stifel analyst Dae Gon Ha initiates coverage on $Inozyme Pharma(INZY.US)$ with a buy rating, and sets the target price at $16.According to TipRanks data, the analyst has a success rate of 46.0% and
Inozyme Pharma to Participate at the 2024 Wells Fargo Healthcare Conference